Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 4Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Meningeal Carcinomatosis 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1Advanced Malignant Solid Tumors 1Advanced Lung Cancer 1Advanced Breast Cancer 1

Interventions

toripalimab 1Premedication 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Tumors × toripalimab × 30 days × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡